143results about "Polypeptide with affinity tag" patented technology

This invention provides vectors (e.g., lentiviral vectors) and expression cassettes for incorporation into vectors for expressing an alpha-globin (α-globin) gene. In certain embodiments method of treatment using such vectors are provided.

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

Provided herein is a system for delivering genetical material, preferably subcutaneously, and its various elements. Also provided are related compositions and methods.

Provided is a method for producing a heterodimeric protein such as a bispecific antibody with which a heterodimeric protein composed of only domains having natural amino acid sequences can also be produced. A production method of the present invention is a method for producing a heterodimeric protein. The production method includes a production step of producing a heterodimeric protein by reacting a dimeric protein having a reaction tag with a modification protein for modifying the dimeric protein. The dimeric protein having a reaction tag includes a first monomeric protein and a second monomeric protein. The first monomeric protein includes a first reaction tag and a first dimer formation domain capable of forming a dimer in this order. The first reaction tag includes a binding tag and a first C intein. The second monomeric protein includes a second reaction tag and a second dimer formation domain capable of forming a dimer together with the first dimer formation domain in this order. The second reaction tag includes a binding partner capable of binding to the binding tag, and a second C intein. The modification protein includes a first modification protein and a second modification protein. The first modification protein includes a first N intein capable of reacting with the first C intein, and a first addition component to be added to the first monomeric protein. The second modification protein includes a second N intein capable of reacting with the second C intein, and a second addition component to be added to the second monomeric protein. The first addition component and the second addition component are different addition components. The first monomeric protein and the second monomeric protein form a dimer. In the production step, the first N intein of the first modification protein reacts with the first C intein of the first monomeric protein, and then the first addition component of the first modification protein is linked to the first monomeric protein, and the second N intein of the second modification protein reacts with the second C intein of the second monomeric protein, and then the second addition component of the second modification protein is linked to the second monomeric protein.

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

The present invention relates to novel enzyme nanoparticles capable of converting methane into methanol, in which key active sites of methane-oxidizing bacteria are fused with each other and expressed on a protein that can be self-assembled in cells to form nanoparticles, and specifically to enzyme nanoparticles including a protein having methane monooxygenase (MMO) activity and active sites of the methane oxidase, a method for production thereof, a recombinant microorganism into which a nucleic acid encoding the protein and the active site of the methane oxidase is introduced, and immobilized enzyme nanoparticles including the enzyme nanoparticles loaded on a carrier.

The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

Provided are a Cas effector protein, a fusion protein containing said protein, and a nucleic acid molecule coding same. Also provided are a complex and a composition for nucleic acid editing, for example, a complex and a composition for gene or genome editing, containing the Cas effector protein or the fusion protein, or the nucleic acid molecule encoding same. Also provided is a method for nucleic acid editing, for example, a method for gene or genome editing, using the Cas effector protein or the fusion protein.

The invention relates to modified apolipoprotein with a targeting body. The targeting body may for example be an antibody or antigen binding fragment that allows targeting of e.g. a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload as such or when incorporated in a lipid nanoparticle. The modified apolipoprotein finds use in the treatment or prevention of diseases, or targeting a pay load to a specific target site.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present application relates to the field of biological medicine and clinical diagnosis, and more particularly, the present application relates to a polypeptide having binding affinity to AXL protein and application thereof; the polypeptide has binding affinity to AXL protein, and therefore can be used for detecting AXL protein, so that the polypeptide has diagnostic or therapeutic use as a drug or molecular targeting reagent.

A process for synthesizing and separating secretory IgA from a mixture of IgA monomer and IgA dimer is provided The process includes covalently binding affinity tagged or epitope tagged recombinant secretory component to the IgA dimer in the mixture and then binding the affinity tagged or an epitope tagged secretory IgA to immobilized moieties on the solid phase support resin to which the affinity tag or epitope tag binds and then eluting the affinity tagged or an epitope tagged secretory IgA with release buffer. A process for synthesizing and separating secretory IgM from a mixture of IgM and other plasma proteins is provided. A process is provided for inhibiting or preventing symptoms of necrotizing enterocolitis in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled human plasma derived dimeric and polymeric.

Described herein is a bifunctional peptide, compositions comprising the same, and methods useful for treatment of peri-implant disease.

In alternative embodiments, provided are synthetic, or non-natural, protein heterodimers or homodimers whose protein / protein binding interactions are controlled through metal or small molecule binding, and methods of making and using them. In alternative embodiments, provided are metal-controlled or small molecule-controlled heterodimers or homodimers, wherein each dimer is fused or joined to half or a portion of a detectable entity, and the when the two dimers are joined or come in contact with each other because of each dimer's binding to a metal, the detectable entity's halves, now also joined or having come in contact with each other, only now can directly or indirectly generate or initiate a detectable signal. In alternative embodiments, provided are biosensors or microfluidic devices comprising synthetic, or non-natural, protein heterodimers or homodimers as provided herein.

The present invention is directed to vegetative insecticidal proteins (Vips) modified to comprise heterologous carbohydrate binding modules and methods of use thereof.

The present disclosure provides surprisingly useful methods for making fusion polypeptides comprising an immunomodulatory moiety and a metal hydroxide-binding moiety, as well as a variety of related technologies, including methods for making fusion polypeptide-metal hydroxide complexes and methods for using such fusion polypeptides and / or fusion polypeptide-metal hydroxide complexes.

The present disclosure provides compositions and methods related to transcription factor systems. Such systems provide modular and tunable protein expression driven by regulated transcriptional activity.

The present invention relates to means and methods for the one-step affinity purification of a polypeptide of interest controlled by light. Accordingly, the present invention relates to a polypeptide comprising an N-terminal or C-terminal light-responsive affinity tag, wherein said N-terminal or C-terminal light-responsive affinity tag may comprise a non-natural light-responsive amino acid. Accordingly, the present invention further relates to such light-responsive affinity tags. Further provided herein are means and methods for the recombinant coupling of such non-natural light-responsive amino acids and / or light-responsive affinity tags to a polypeptide of interest. Provided herein is also a solid (stationary) phase to be employed with said light-responsive affinity tag in a method for the purification of said polypeptide of interest. Further provided is a kit comprising any of the above.

Disclosed are a method for preparing an immobilized enzyme or an immobilized protein and the immobilized enzyme or the immobilized protein. The method comprises: covalently binding SpyCatcher on a carrier; constructing a target enzyme or a target protein fused with SpyTag at an N terminal or a C terminal; and contacting the carrier covalently bound with SpyCatcher with the target enzyme or the target protein fused with SpyTag. The immobilized enzyme or the immobilized protein comprises a carrier, SpyCatcher covalently bound with the carrier, and a target enzyme or a target protein fused with SpyTag at an N terminal or a C terminal, which is covalently bound with the carrier through the SpyTag and the SpyCatcher. The present application also relates to a carrier covalently bound with SpyCatcher and the use thereof for selectively immobilizing a target enzyme or a target protein fused with SpyTag at an N terminal or a C terminal from a protein mixture.

The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (Ena) proteins modified to contain metal-binding polypeptide (MBP) inserts providing for stable, flexible and robust protein assemblies with metal-binding activity. In particular, the invention relates to methods for designing Ena-fusion proteins capable of self-assembling into fibers, and for recombinant production of said self-assembling Ena-MBP fusion protein subunits, assemblies and fibers, ensuring a sustainable source of biological material for use in metal mineralization, metal sequestration, and metal-removal applications such as waste water treatment, water softening, or bioremediation.

The present disclosure relates generally to methods and compositions for loading cargo entities into lipid bilayer particles, such as cell-derived membrane particles, e.g., secreted extracellular vesicles.

To provide a composition that significantly improves bone healing and accelerates tissue regrowth.SOLUTION: The present invention provides a chimeric polypeptide that comprises (i) one or more β-tricalcium phosphate (β-TCP)-binding sequence(s), wherein at least one of the one or more β-TCP-binding sequence(s) is selected from the group consisting of specific sequences and (ii) a mammalian growth factor. The present invention also provides a composition containing the chimeric polypeptide.SELECTED DRAWING: Figure 1A

The present invention relates to the provision of trifunctional crosslinker compounds comprising (i) a moiety reactive with an amino acid side chain for selective labelling of proteins, (ii) a cleavable linker moiety and (iii) an affinity moiety for the detection, isolation and purification of captured proteins. The invention further relates to uses of the cleavable crosslinking reagents in methods for detecting, labelling, identifying and characterizing proteins and protein interactions in or on the surface of intact cells, cell lysates and / or protein mixtures.

Disclosed herein is an artificial transmembrane protein for use in a biomolecule detection device for detecting intracellular or intravesicular biomolecule interactions, the artificial transmembrane protein comprising an extracellular or extravesicular binding structure, a hydrophobic transmembrane domain, and an intracellular or intravesicular domain having an intracellular or intravesicular receptor structure, wherein the receptor structure is configured to interact with an intracellular or intravesicular component of a biomolecule interaction to be detected, and wherein the extracellular or extravesicular binding structure is configured to bind to a membrane recognition element arranged along a plurality of predetermined lines of the biomolecule detection device.

The present invention relates to means and methods for the one-step affinity purification of a polypeptide of interest controlled by light. Accordingly, the present invention relates to a polypeptide comprising an N-terminal or C-terminal light-responsive affinity tag, wherein said N-terminal or C-terminal light-responsive affinity tag may comprise a non-natural light-responsive amino acid. Accordingly, the present invention further relates to such light-responsive affinity tags. Further provided herein are means and methods for the recombinant coupling of such non-natural light-responsive amino acids and / or light-responsive affinity tags to a polypeptide of interest. Provided herein is also a solid (stationary) phase to be employed with said light-responsive affinity tag in a method for the purification of said polypeptide of interest. Further provided is a kit comprising any of the above.

The present disclosure provides surprisingly useful fusion polypeptides including an immunomodulatory moiety and a metal-hydroxide binding moiety, as well as various related technologies, including methods of making and of using such fusion polypeptides.

The present invention relates to a process wherein one or more dye precursors, e.g., indole, are provided to a textile and converted by one or more enzymes, e.g., an oxidizing enzyme, to provide the textile with a dye, e.g. indigo. At least the oxidizing enzyme is a hybrid enzyme including a binding domain that is suitable to bind the enzyme to the textile and / or increase the affinity of the enzyme for the textile, in particular, a cellulose binding domain (CBD).

The invention provided herein relates to methods for cell-free protein synthesis and characterisation. Provided is an automated system for analysing expression and purification of proteins.

The disclosure, in some aspects, provides antigen-specific amino acid sequences for tick-borne relapsing fever Borrelia species.